迪斯科伊丁域受体氨酸激酶1 (DDR1) 是脂肉瘤的新疗法标:组织微阵列研究
Dylan C Dean1, Wenlong Feng1,2, Robert L Walker1
1Sarcoma Biology Laboratory, Department of Orthopaedics, Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine, Miami, FL, USA.
Clinical orthopaedics and related research
|September 28, 2023
概括
迪斯科伊丁域受体氨酸激酶1 (DDR1) 在脂瘤中高度表达,驱动癌细胞生长. 抑制DDR1显著降低了脂肉瘤的扩散,突出其作为新治疗点的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 脂肉瘤是一种常见的软组织肉瘤,在手术切除方面存在挑战,并且有效的化疗选择有限.
- 迪斯科伊丁域受体氨酸激酶1 (DDR1) 在各种癌症中起作用,但其在脂瘤瘤中的重要性仍未被探索.
研究的目的:
- 为了研究DDR1在脂肪肉瘤中的表达.
- 确定DDR1和患者存活率之间的关联.
- 阐明DDR1在脂肪肉瘤瘤发生中的功能性作用.
主要方法:
- 脂肉瘤组织微阵列的免疫组合化学染色,以评估DDR1表达.
- 卡普兰-梅尔分析以将DDR1表达与生存结果相关联.
- 使用CRISPR-Cas9技术生成DDR1淘汰细胞系和体外/3D细胞培养模型来评估使用选择性抑制剂 (7RH) 的DDR1抑制.
主要成果:
- 与良性脂瘤相比,脂瘤瘤组织中的DDR1表达显著增加.
- 高的DDR1表达与较差的患者存活率没有相关性.
- 用7RH显著减少脂瘤瘤细胞生长和增殖的DDR1淘汰或抑制.
结论:
- 异常的DDR1表达是脂质肉瘤的特征,有助于瘤性过程.
- DDR1代表了一种有前途的治疗点,用于治疗脂肪肉瘤.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Receptor Tyrosine Kinases
13.1K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.1K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K


